Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 10 2020
08 10 2020
Historique:
received:
07
04
2020
accepted:
24
09
2020
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Since optimal treatment at an early stage leads to remission of symptoms and recovery of function, putative biomarkers leading to early diagnosis and prediction of therapeutic responses are desired. The current study aimed to use a metabolomic approach to extract metabolites involved in both the diagnosis of major depressive disorder (MDD) and the prediction of therapeutic response for escitalopram. We compared plasma metabolites of MDD patients (n = 88) with those in healthy participants (n = 88) and found significant differences in the concentrations of 20 metabolites. We measured the Hamilton Rating Scale for Depression (HRSD) on 62 patients who completed approximately six-week treatment with escitalopram before and after treatment and found that kynurenic acid and kynurenine were significantly and negatively associated with HRSD reduction. Only one metabolite, kynurenic acid, was detected among 73 metabolites for overlapped biomarkers. Kynurenic acid was lower in MDD, and lower levels showed a better therapeutic response to escitalopram. Kynurenic acid is a metabolite in the kynurenine pathway that has been widely accepted as being a major mechanism in MDD. Overlapping biomarkers that facilitate diagnosis and prediction of the treatment response may help to improve disease classification and reduce the exposure of patients to less effective treatments in MDD.
Identifiants
pubmed: 33033336
doi: 10.1038/s41598-020-73918-z
pii: 10.1038/s41598-020-73918-z
pmc: PMC7545168
doi:
Substances chimiques
Antidepressive Agents, Second-Generation
0
Biomarkers
0
Citalopram
0DHU5B8D6V
Kynurenic Acid
H030S2S85J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16822Références
Young, J. J. et al. Is there progress? An overview of selecting biomarker candidates for major depressive disorder. Front. Psychiatry 7, 72. https://doi.org/10.3389/fpsyt.2016.00072 (2016).
doi: 10.3389/fpsyt.2016.00072
pubmed: 27199779
pmcid: 4843170
Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917 (2006).
doi: 10.1176/ajp.2006.163.11.1905
Clevenger, S. S., Malhotra, D., Dang, J., Vanle, B. & IsHak, W. W. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder. Ther. Adv. Psychopharmacol. 8, 49–58 (2018).
doi: 10.1177/2045125317737264
Artigas, F., Nutt, D. J. & Shelton, R. Mechanism of action of antidepressants. Psychopharmacol. Bull. 36, 123–132 (2002).
pubmed: 12490828
Athreya, A. P. et al. Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication. Clin. Pharmacol. Ther. 106, 855–865 (2019).
doi: 10.1002/cpt.1482
Al-Harbi, K. S. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adherence 6, 369–388 (2012).
doi: 10.2147/PPA.S29716
Carlomagno, N. et al. Diagnostic, predictive, prognostic, and therapeutic molecular biomarkers in third millennium: a breakthrough in gastric cancer. Biomed. Res. Int. 2017, 7869802. https://doi.org/10.1155/2017/7869802 (2017).
doi: 10.1155/2017/7869802
pubmed: 29094049
pmcid: 5637861
Gadad, B. S. et al. Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks. J. Affect. Disord. 233, 3–14 (2018).
doi: 10.1016/j.jad.2017.07.001
Habert, J. et al. Functional recovery in major depressive disorder: focus on early optimized treatment. Prim. Care Companion CNS Disord. 18, 15r01926. https://doi.org/10.4088/PCC.15r01926 (2016).
doi: 10.4088/PCC.15r01926
Fernie, A. R., Trethewey, R. N., Krotzky, A. J. & Willmitzer, L. Metabolite profiling: from diagnostics to systems biology. Nat. Rev. Mol. Cell Biol. 5, 763–769 (2004).
doi: 10.1038/nrm1451
Paige, L. A., Mitchell, M. W., Krishnan, K. R. R., Kaddurah-Daouk, R. & Steffens, D. C. A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry 22, 418–423 (2007).
doi: 10.1002/gps.1690
Pan, J.-X. et al. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study. Transl. Psychiatry 8, 130. https://doi.org/10.1038/s41398-018-0183-x (2018).
doi: 10.1038/s41398-018-0183-x
pubmed: 29991685
pmcid: 6039504
Zheng, H. et al. Predictive diagnosis of major depression using NMR-based metabolomics and least-squares support vector machine. Clin. Chim. Acta 464, 223–227 (2017).
doi: 10.1016/j.cca.2016.11.039
Setoyama, D. et al. Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis. PLoS ONE 11, e0165267. https://doi.org/10.1371/journal.pone.0165267 (2016).
doi: 10.1371/journal.pone.0165267
pubmed: 27984586
pmcid: 5161310
Kawamura, N. et al. Plasma metabolome analysis of patients with major depressive disorder. Psychiatry Clin. Neurosci. 72, 349–361 (2018).
doi: 10.1111/pcn.12638
MacDonald, K. et al. Biomarkers for major depressive and bipolar disorders using metabolomics: a systematic review. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 180, 122–137 (2019).
doi: 10.1002/ajmg.b.32680
Kaddurah-Daouk, R. et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 1, e26. https://doi.org/10.1038/tp.2011.22 (2011).
doi: 10.1038/tp.2011.22
pubmed: 22162828
pmcid: 3232004
Kaddurah-Daouk, R. et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 3, e223. https://doi.org/10.1038/tp.2012.142 (2013).
doi: 10.1038/tp.2012.142
pubmed: 23340506
pmcid: 3566722
Zhu, H. et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder—possible role for methoxyindole pathway. PLoS ONE 8, e68283. https://doi.org/10.1371/journal.pone.0068283 (2013).
doi: 10.1371/journal.pone.0068283
pubmed: 23874572
pmcid: 3714282
Rotroff, D. M. et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Transl. Psychiatry 6, e894. https://doi.org/10.1038/tp.2016.145 (2016).
doi: 10.1038/tp.2016.145
pubmed: 27648916
pmcid: 5048196
Bhattacharyya, S. et al. Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Transl. Psychiatry 9, 173. https://doi.org/10.1038/s41398-019-0507-5 (2019).
doi: 10.1038/s41398-019-0507-5
pubmed: 31273200
pmcid: 6609722
Kirino, E. Escitalopram for the management of major depressive disorder: areview of its efficacy, safety, and patient acceptability. Patient Prefer. Adherence 6, 853–861 (2012).
doi: 10.2147/PPA.S22495
Bender, D. A. & McCreanor, G. M. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem. Soc. Trans. 13, 441–443 (1985).
doi: 10.1042/bst0130441
Chiarugi, A., Meli, E. & Moroni, F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 77, 1310–1318 (2001).
doi: 10.1046/j.1471-4159.2001.00335.x
Tanaka, M. & Boh, Z. Are kynurenines accomplices or principal villains in dementia? Maintenance of kynurenine metabolism. Molecules 25, 564. https://doi.org/10.3390/molecules25030564 (2020).
doi: 10.3390/molecules25030564
pmcid: 7036975
Perkins, M. N. & Stone, T. W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247, 184–187 (1982).
doi: 10.1016/0006-8993(82)91048-4
Ogyu, K. et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 90, 16–25 (2018).
doi: 10.1016/j.neubiorev.2018.03.023
Liu, H. et al. The metabolic factor kynurenic acid of kynurenine pathway predicts major depressive disorder. Front. Psychiatry 9, 552. https://doi.org/10.3389/fpsyt.2018.00552 (2018).
doi: 10.3389/fpsyt.2018.00552
pubmed: 30510519
pmcid: 6252326
Tanaka, M., Bohár, Z., Martos, D., Telegdy, G. & Vécsei, L. Antidepressant—like effects of kynurenic acid in a modified forced swim test. Pharmacol. Rep. 72, 449–455 (2020).
doi: 10.1007/s43440-020-00067-5
Halaris, A. et al. Does escitalopram reduce neurotoxicity in major depression?. J. Psychiatr. Res. 66–67, 118–126 (2015).
doi: 10.1016/j.jpsychires.2015.04.026
Myint, A. M. et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98, 143–151 (2007).
doi: 10.1016/j.jad.2006.07.013
Kocki, T., Wnuk, S. & Kloc, R. New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. J. Neural Transm. 119, 235–243 (2012).
doi: 10.1007/s00702-011-0668-8
Sun, Y. et al. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine. Brain Behav. Immun. 87, 404–412 (2020).
doi: 10.1016/j.bbi.2020.01.011
Zhao, J. & Zhao, J. Plasma kynurenic acid/tryptophan ratio: a sensitive and reliable biomarker for the assessment of renal function plasma kynurenic acid/tryptophan ratio : a sensitive and reliable biomarker for the assessment of renal function. Ren. Fail. 35, 648–653 (2013).
doi: 10.3109/0886022X.2013.790301
Zakrocka, I., Targowska-duda, K. M. & Wnorowski, A. Angiotensin II type 1 receptor blockers inhibit KAT II activity in the brain—its possible clinical applications. Neurotox. Res. 32, 639–648 (2017).
doi: 10.1007/s12640-017-9781-2
Cui, X. et al. Long non-coding RNA: Potential diagnostic and therapeutic biomarker for major depressive disorder. Med. Sci. Monit. 22, 5240–5248 (2016).
doi: 10.12659/MSM.899372
Jameson, J. L. & Longo, D. L. Precision medicine—personalized, problematic, and promising. N. Engl. J. Med. 372, 2229–2234 (2015).
doi: 10.1056/NEJMsb1503104
Kuwano, N. et al. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: an exploratory pilot case-control study. J. Affect. Disord. 231, 74–82 (2018).
doi: 10.1016/j.jad.2018.01.014
Setoyama, D. et al. Personality classification enhances blood metabolome analysis and biotyping for major depressive disorders: two-species investigation. J. Affect. Disord. (in press).
Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. ROCR: visualizing classifier performance in R. Bioinformatics 21, 3940–3941 (2005).
doi: 10.1093/bioinformatics/bti623